Global Favipiravir Market is expected to grow at a CAGR of 4.40% during the forecast period and the market size is expected to reach nearly US$ 2.68 Bn by 2029. The global Favipiravir market report is a comprehensive analysis of the industry, market, and key players. The report has covered the market by demand and supply-side by segments. The global Favipiravir market report also provides trends by market segments, technology, and investment with a competitive landscape.Favipiravir Market Overview:
Favipiravir is a generic drug with a brand name sold under Avigan and molecular formula C5H4FN3O2. The drug is also sold under the name of Avigan, Avifavir, Areplivir, Fabiflu, and favipiravir. Favipiravir is a drug used in the treatment of viral infection as an antiviral medication. This drug was first discovered in 2014 in Japan for the treatment of influenza.To know about the Research Methodology :- Request Free Sample Report Favipiravir drug was first developed and manufactured by Toyoma Chemicals (FujiFilm Group) and approved in the year 2014. And In 2016, Fujifilm licensed Active pharmaceutical ingredient (API) to Zhejiang Hisun Pharmaceutical Co. of china. And became a generic drug in 2019. Recently, the Favipiravir drug has been used in the treatment of SARS-COV-2 (COVID-19). The mechanism of action is through selective inhibitions of viral RNA-dependent RNA polymerase. Favipiravir is a prodrug that is metabolized to its active form, favipiravir-ribofuranosyl-5'triphosphate (Favipiravir-RTP) when administered into the body. The drug is available in both forms oral as well intravenous. However, along with the advantages, the drug also comes with some side effects like teratogenic and embryotoxic effects in pregnant women.
Favipiravir Market Dynamics:
Favipiravir a generics drug used in the treatment of COVID-19 with mild or moderate symptoms to inhibit the growth of coronavirus proliferation. The drug has become the largest-selling drug in India with sales of up to 140cr with locally made version. According to All India Origin Chemists and Distributors (AIOCD) Favipiravir is the only drug molecule to cross 100 cr. and registered the fastest-growing Domestic Brand in India after the launch in June 2020. To deal with the current COVID-19 pandemic situation Emergency Use Authorization (EAU) of the drug has increased to grand the drug for production and clinical trials. Favipiravir is the drug that has shown promising results in COVID-19 and acts as an opportunity to market players for developing the business and grow with the market. The factor responsible for the growth of the Favipiravir market is the extraordinary demand and supply of the drug to meet the pandemic situation. For Instance, major key players like Glenmark Pharmaceuticals on June 22, 2020 launched the first oral antiviral drug Favipiravir with the company brand name FabiFlu with manufacturing and marketing approvals from India's Drug Regulatory Authorities. Recently Bajaj Healthcare has also announced to launch the drug favipiravir under the brand name Favijaj to meet the growing demand of pandemic and the company has received the approval from Drug Controller General of India (DCGI). This factor acts as an opportunity for other budding organizations to enter the market. Strict rules and regulations imposed by the government due to huge contaminations of COVID-19 all over the world are acting as a major challenge for the manufacturing units to progress with large scale production due to lack of raw material supply, inaccessibility of labors, fluctuating transport facilities are acting as a challenge to the key market players. COVID-19 scenario analysis: The outbreak of the COVID-19 pandemic has positively impacted the global Favipiravir market. Subsequently, with the arrival of the global pandemic, the maximum of the manufacturing units have enhanced the production facility to meet growing demand. This has resulted in substantial growth in the Favipiravir market.Favipiravir Market Segment Analysis:
By tablet Form, the segment table form is trifurcated into 200mg, 400mg, and 800mg. 800mg tablet is dominating the market due to dose convenience of 1600mg per day. i.e. 800mg tablet twice a day and increased the market by revenue. Due to the high demand for 800mg tablets and huge shortage in supply and transport 400mg tablet sale was increased for a while. By Application, the segment application can be set apart into the COVID-19, Ebola, Nipah, and others. The sub-segment COVID-19 is dominating the market due to the high growth rate of contamination and no vaccine is available in the market. India has reported 3,57,229 new cases and 3449 deaths have been reported recently. However, the death rate has been decreased due to low mobility around the world.By Distribution Channel, the segment is trifurcated into Hospitals, Clinics, and Retail shops. The sub-segment hospital is dominating the market due to higher admission of a patient into the hospital and the facilities of insurance policy and proper treatment provided and 24/7 monitoring by the hospital authorities.
Favipiravir Market Regional Insights:
The Asia Pacific is dominating the market with the highest cases in China, India and leading with the market share in terms of revenue. The presence of major market players like Fujifilm Toyoma Chemicals Co., Glenmark Pharmaceuticals. Cipla Limited is supplementing the region to grow. The rate of increasing disposable income, rising awareness about healthcare facilities, huge investment into research and development, growing health infrastructure, and Emergency use Approvals by the government are the factors responsible for the regional growth. The leading countries of Asia Pacific are Japan, China, and India who contribute to the region in market growth. The objective of the report is to present a comprehensive analysis of the global Favipiravir market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding the global Favipiravir market dynamics, structure by analyzing the market segments and project the global Favipiravir market size. Clear representation of competitive analysis of key players by Form, price, financial position, Form portfolio, growth strategies, and regional presence in the global Favipiravir market make the report investor’s guide.Favipiravir Market Scope: Inquire before buying
Global Favipiravir Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2018 to 2022 Market Size in 2022: US$ 1.98 Bn. Forecast Period 2023 to 2029 CAGR: 4.40% Market Size in 2029: US$ 2.68 Bn. Segments Covered: by Tablet Form 200mg 400mg 800mg by Application COVID-19 Ebola Nepah Other by Distribution Channel Hospital Clinic Retail Shop Favipiravir Market, by Region
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) North America (United States, Canada and Mexico) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)Favipiravir Market Key Players
1. Glenmark 2. Fujifilm 3. Dr. Reddy 4. R-Pharma 5. Cipla 6. Lupin 7. Sun Pharma 8. Hisun Pharm 9. CSPC Pharmaceutical Group 10. Reyoung Pharmaceutical 11. Sihuan Pharmaceutical Frequently Asked Questions: 1. Which region has the largest share in Global Favipiravir Market? Ans: Asia Pacific region holds the highest share in 2022. 2. What is the growth rate of Global Favipiravir Market? Ans: The Global market is growing at a CAGR of 4.40% during forecasting period 2023-2029. 3. What is scope of the Global Favipiravir market report? Ans: Global market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Global Favipiravir market? Ans: The important key players in the Global market are – Glenmark, Fujifilm, Dr. Reddy, R-Pharma, Cipla, Lupin, Sun Pharma, Hisun Pharm, CSPC Pharmaceutical Group, Reyoung Pharmaceutical, and Sihuan Pharmaceutical 5. What is the study period of this market? Ans: The Global market is studied from 2022 to 2029.
1. Preface 1.1. Market Definition and Key Research Objectives 1.2. Research Highlights 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Forms 2.3.2. Primary Research 2.3.2.1. Data from Primary Forms 2.3.2.2. Breakdown of Primary Forms 3. Executive Summary: Global Favipiravir Market Size, by Market Value (US$ Mn) 3.1. Global Market Segmentation 3.2. Global Market Segmentation Share Analysis, 2022 3.2.1. Global 3.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 3.3. Geographical Snapshot of the Favipiravir Market 3.4. Geographical Snapshot of the Favipiravir Market, By Manufacturer share 4. Global Favipiravir Market Overview, 2022-2029 4.1. Market Dynamics 4.1.1. Drivers 4.1.1.1. Global 4.1.1.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.2. Restraints 4.1.2.1. Global 4.1.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.3. Opportunities 4.1.3.1. Global 4.1.3.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.4. Challenges 4.1.4.1. Global 4.1.4.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.5. Industry Trends and Emerging Technologies 4.1.6. Porters Five Forces Analysis 4.1.6.1. Threat of New Entrants 4.1.6.2. Bargaining Power of Buyers/Consumers 4.1.6.3. Bargaining Power of Suppliers 4.1.6.4. Threat of Substitute Forms 4.1.6.5. Intensity of Competitive Rivalry 4.1.7. Value Chain Analysis 4.1.8. Technological Roadmap 4.1.9. Regulatory landscape 4.1.10. Impact of the Covid-19 Pandemic on the Favipiravir Market 5. Supply Side and Demand Side Indicators 6. Global Favipiravir Market Analysis and Forecast, 2022-2029 6.1. Global Favipiravir Market Size & Y-o-Y Growth Analysis. 7. Global Favipiravir Market Analysis and Forecasts, 2022-2029 7.1. Market Size (Value) Estimates & Forecast By Tablet Form, 2022-2029 7.1.1. 200mg 7.1.2. 400mg 7.1.3. 800mg 7.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 7.2.1. COVID-19 7.2.2. Ebola 7.2.3. Nepah 7.2.4. Other 7.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 7.3.1. Hospital 7.3.2. Clinic 7.3.3. Retail Shop 8. Global Favipiravir Market Analysis and Forecasts, By Region 8.1. Market Size (Value) Estimates & Forecast By Region, 2022-2029 8.1.1. North America 8.1.2. Europe 8.1.3. Asia-Pacific 8.1.4. Middle East & Africa 8.1.5. South America 9. Asia Pacific Favipiravir Market Analysis and Forecasts, 2022-2029 9.1. Market Size (Value) Estimates & Forecast By Tablet Form, 2022-2029 9.1.1. 200mg 9.1.2. 400mg 9.1.3. 800mg 9.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 9.2.1. COVID-19 9.2.2. Ebola 9.2.3. Nepah 9.2.4. Other 9.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 9.3.1. Hospital 9.3.2. Clinic 9.3.3. Retail Shop 10. North America Favipiravir Market Analysis and Forecasts, By Country 10.1. Market Size (Value) Estimates & Forecast By Country, 2022-2029 10.1.1. US 10.1.2. Canada 10.1.3. Mexico 11. U.S. Favipiravir Market Analysis and Forecasts, 2022-2029 11.1. Market Size (Value) Estimates & Forecast By Form, 2022-2029 11.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 11.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 12. Canada Favipiravir Market Analysis and Forecasts, 2022-2029 12.1. Market Size (Value) Estimates & Forecast By Tablet Form, 2022-2029 12.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 12.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 13. Mexico Favipiravir Market Analysis and Forecasts, 2022-2029 13.1. Market Size (Value) Estimates & Forecast By Tablet Form, 2022-2029 13.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 13.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 14. Europe Favipiravir Market Analysis and Forecasts, 2022-2029 14.1. Market Size (Value) Estimates & Forecast By Tablet Form, 2022-2029 14.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 14.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 15. Europe Favipiravir Market Analysis and Forecasts, By Country 15.1. Market Size (Value) Estimates & Forecast By Country, 2022-2029 15.1.1. U.K 15.1.2. France 15.1.3. Germany 15.1.4. Italy 15.1.5. Spain 15.1.6. Sweden 15.1.7. CIS Countries 15.1.8. Rest of Europe 16. U.K Favipiravir Market Analysis and Forecasts, 2022-2029 16.1. Market Size (Value) Estimates & Forecast By Tablet Form, 2022-2029 16.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 16.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 17. France Favipiravir Market Analysis and Forecasts, 2022-2029 17.1. Market Size (Value) Estimates & Forecast By Tablet Form, 2022-2029 17.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 17.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 18. Germany Favipiravir Market Analysis and Forecasts, 2022-2029 18.1. Market Size (Value) Estimates & Forecast By Tablet Form, 2022-2029 18.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 18.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 19. Italy Favipiravir Market Analysis and Forecasts, 2022-2029 19.1. Market Size (Value) Estimates & Forecast By Tablet Form, 2022-2029 19.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 19.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 20. Spain Favipiravir Market Analysis and Forecasts, 2022-2029 20.1. Market Size (Value) Estimates & Forecast By Tablet Form, 2022-2029 20.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 20.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 21. Sweden Favipiravir Market Analysis and Forecasts, 2022-2029 21.1. Market Size (Value) Estimates & Forecast By Tablet Form, 2022-2029 21.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 21.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 22. CIS Countries Favipiravir Market Analysis and Forecasts, 2022-2029 22.1. Market Size (Value) Estimates & Forecast By Tablet Form, 2022-2029 22.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 22.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 23. Rest of Europe Favipiravir Market Analysis and Forecasts, 2022-2029 23.1. Market Size (Value) Estimates & Forecast By Tablet Form, 2022-2029 23.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 23.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 24. Asia Pacific Favipiravir Market Analysis and Forecasts, 2022-2029 24.1. Market Size (Value) Estimates & Forecast By Tablet Form, 2022-2029 24.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 24.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 25. Asia Pacific Favipiravir Market Analysis and Forecasts, by Country 25.1. Market Size (Value) Estimates & Forecast By Country, 2022-2029 25.1.1. China 25.1.2. India 25.1.3. Japan 25.1.4. South Korea 25.1.5. Australia 25.1.6. ASEAN 25.1.7. Rest of Asia Pacific 26. China Favipiravir Market Analysis and Forecasts, 2022-2029 26.1. Market Size (Value) Estimates & Forecast By Tablet Form, 2022-2029 26.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 26.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 27. India Favipiravir Market Analysis and Forecasts, 2022-2029 27.1. Market Size (Value) Estimates & Forecast By Tablet Form, 2022-2029 27.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 27.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 28. Japan Favipiravir Market Analysis and Forecasts, 2022-2029 28.1. Market Size (Value) Estimates & Forecast By Tablet Form, 2022-2029 28.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 28.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 29. South Korea Favipiravir Market Analysis and Forecasts, 2022-2029 29.1. Market Size (Value) Estimates & Forecast By Tablet Form, 2022-2029 29.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 29.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 30. Australia Favipiravir Market Analysis and Forecasts, 2022-2029 30.1. Market Size (Value) Estimates & Forecast By Tablet Form, 2022-2029 30.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 30.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 31. ASEAN Favipiravir Market Analysis and Forecasts, 2022-2029 31.1. Market Size (Value) Estimates & Forecast By Tablet Form, 2022-2029 31.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 31.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 32. Rest of Asia Pacific Favipiravir Market Analysis and Forecasts, 2022-2029 32.1. Market Size (Value) Estimates & Forecast By Tablet Form, 2022-2029 32.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 32.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 33. Middle East Africa Favipiravir Market Analysis and Forecasts, 2022-2029 33.1. Market Size (Value) Estimates & Forecast By Tablet Form, 2022-2029 33.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 33.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 34. Middle East Africa Favipiravir Market Analysis and Forecasts, by Country 34.1. Market Size (Value) Estimates & Forecast by Country, 2022-2029 34.1.1. South Africa 34.1.2. GCC Countries 34.1.3. Egypt 34.1.4. Nigeria 34.1.5. Rest of ME&A 35. South Africa Favipiravir Market Analysis and Forecasts, 2022-2029 35.1. Market Size (Value) Estimates & Forecast By Tablet Form, 2022-2029 35.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 35.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 36. GCC Countries Favipiravir Market Analysis and Forecasts, 2022-2029 36.1. Market Size (Value) Estimates & Forecast By Tablet Form, 2022-2029 36.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 36.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 37. Egypt Favipiravir e-Market Analysis and Forecasts, 2022-2029 37.1. Market Size (Value) Estimates & Forecast By Tablet Form, 2022-2029 37.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 37.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 38. Nigeria Favipiravir Market Analysis and Forecasts, 2022-2029 38.1. Market Size (Value) Estimates & Forecast By Tablet Form, 2022-2029 38.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 38.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 39. Rest of ME&A Favipiravir Market Analysis and Forecasts, 2022-2029 39.1. Market Size (Value) Estimates & Forecast By Tablet Form, 2022-2029 39.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 39.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 40. South America Favipiravir Market Analysis and Forecasts, 2022-2029 40.1. Market Size (Value) Estimates & Forecast By Tablet Form, 2022-2029 40.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 40.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 41. South America Favipiravir Market Analysis and Forecasts, by Country 41.1. Market Size (Value) Estimates & Forecast by Country, 2022-2029 41.1.1. Brazil 41.1.2. Argentina 41.1.3. Rest of South America 42. Brazil Favipiravir Market Analysis and Forecasts, 2022-2029 42.1. Market Size (Value) Estimates & Forecast By Tablet Form, 2022-2029 42.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 42.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 43. Argentina Favipiravir Market Analysis and Forecasts, 2022-2029 43.1. Market Size (Value) Estimates & Forecast By Tablet Form, 2022-2029 43.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 43.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 44. Rest of South America Favipiravir Market Analysis and Forecasts, 2022-2029 44.1. Market Size (Value) Estimates & Forecast By Tablet Form, 2022-2029 44.2. Market Size (Value) Estimates & Forecast By Application, 2022-2029 44.3. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029 45. Competitive Landscape 45.1. Geographic Footprint of Major Players in the Global Favipiravir Market 45.2. Competition Matrix 45.2.1. Competitive Benchmarking of Key Players By Price, Presence, Market Share, Fiber Tablet Forms, and R&D Investment 45.2.2. New Tablet Form Launches and Tablet Form Enhancements 45.2.3. Market Consolidation 45.2.3.1. M&A by Regions, Investment, and Verticals 45.2.3.2. M&A, Forward Integration and Backward Integration 45.2.3.3. Partnership, Joint Ventures, and Strategic Alliances/ Sales Agreements 45.3. Company Profile : Key Players 45.3.1. Glenmark 45.3.1.1. Company Overview 45.3.1.2. Financial Overview 45.3.1.3. Geographic Footprint 45.3.1.4. Tablet Form Portfolio 45.3.1.5. Business Strategy 45.3.1.6. Recent Developments 45.3.2. Fujifilm 45.3.3. Dr. Reddy 45.3.4. R-Pharma 45.3.5. Cipla 45.3.6. Lupin 45.3.7. Sun Pharma 45.3.8. Hisun Pharm 45.3.9. CSPC Pharmaceutical Group 45.3.10. Reyoung Pharmaceutical 45.3.11. Sihuan Pharmaceutical Primary Key Insights